Tpg Gp A LLC Invests $69.93 Million in Sionna Therapeutics, Inc. $SION

Key Points

• Tpg Gp A LLC has invested approximately $69.93 million in Sionna Therapeutics, acquiring 6,684,962 shares, which now represents 1.4% of their total holdings.
• Several institutional investors, including Jennison Associates LLC and TD Asset Management Inc., have also acquired new stakes in Sionna Therapeutics during the first quarter, reflecting growing institutional interest.
• Sionna Therapeutics reported earnings of ($0.41) per share for the last quarter, surpassing analyst expectations of ($0.68), and currently has a consensus rating of "Buy" with an average price target of $38.50.

TPG GP A LLC purchased a new position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 6,684,962 shares of the company's stock, valued at approximately $69,925,000. Sionna Therapeutics comprises about 1.4% of TPG GP A LLC's holdings, making the stock its 17th biggest holding. TPG GP A LLC owned 15.15% of Sionna Therapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of SION. Jennison Associates LLC purchased a new position in Sionna Therapeutics during the 1st quarter worth approximately $8,995,000. TD Asset Management Inc purchased a new position in Sionna Therapeutics during the 1st quarter worth approximately $579,000. Charles Schwab Investment Management Inc. purchased a new position in Sionna Therapeutics during the 1st quarter worth approximately $676,000. CenterBook Partners LP purchased a new position in Sionna Therapeutics during the 1st quarter worth approximately $1,195,000. Finally, Aberdeen Group plc acquired a new stake in Sionna Therapeutics in the 1st quarter valued at $7,803,000.

Sionna Therapeutics Stock Down 3.3%

SION traded down $0.84 during trading on Wednesday, reaching $24.55. The stock had a trading volume of 617,701 shares, compared to its average volume of 187,022. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $26.50. The business has a 50-day moving average of $20.08 and a 200-day moving average of $15.82.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.27.

Analyst Upgrades and Downgrades

SION has been the topic of several recent research reports. Royal Bank Of Canada initiated coverage on shares of Sionna Therapeutics in a research report on Wednesday. They set a "sector perform" rating and a $22.00 price target on the stock. Wall Street Zen raised Sionna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Finally, Raymond James Financial began coverage on Sionna Therapeutics in a research report on Tuesday. They issued a "strong-buy" rating and a $45.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Sionna Therapeutics presently has an average rating of "Buy" and an average price target of $36.00.

Insider Buying and Selling at Sionna Therapeutics

In related news, CFO Elena Ridloff sold 16,098 shares of the firm's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $25.97, for a total value of $418,065.06. Following the sale, the chief financial officer owned 48,116 shares in the company, valued at approximately $1,249,572.52. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Tpg Gp A, Llc purchased 60,000 shares of the company's stock in a transaction dated Friday, June 27th. The shares were acquired at an average price of $15.84 per share, for a total transaction of $950,400.00. Following the purchase, the insider directly owned 6,744,962 shares in the company, valued at approximately $106,840,198.08. The trade was a 0.90% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 58,000 shares of company stock valued at $1,466,671. Corporate insiders own 3.90% of the company's stock.

Sionna Therapeutics Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.